← Leaderboards
Peter K Vogt
Scripps Research Institute
$23,127,584
Attributed
$23,127,584
Total exposure
16
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.8M · FY2005–22$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$33,308,547 · 17
By mechanism
P01$12,470,329 · 5
R01$11,923,151 · 6
R35$7,796,660 · 1
R21$1,076,725 · 2
P41$36,682 · 2
R13$5,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Scripps Research Institute
Same institution · by research overlap
- Marianne Manchester$18,521,680
- James Alfred Hoch$15,381,289
- Kim D Janda$47,128,009
- Jiahuai Han$8,730,510
- Peter Kuhn$23,063,770
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsOncogenesProteinsMolecularOncoproteinsOncogenicPublic Health Relevance1-Phosphatidylinositol 3-KinaseGenetic TranscriptionProtein Protein InteractionComplexChemical Registry /ResourceRegulationTumorigenesisCellsMutantAntineoplasticsBaseInhibitor/AntagonistProtein Structure FunctionSignal TransductionPlayPhosphotransferasesPolymerase Chain Reaction
Grant awards (70)
Cancer genes: translating basics to applications$1,082,187
R35 · FY2022 · CA · contact PI
Cancer genes: translating basics to applications$1,154,070
R35 · FY2021 · CA · contact PI
Cancer genes: translating basics to applications$1,152,156
R35 · FY2020 · CA · contact PI
Cancer genes: translating basics to applications$1,119,086
R35 · FY2019 · CA · contact PI
Cancer genes: translating basics to applications$1,154,070
R35 · FY2018 · CA · contact PI
Cancer genes: translating basics to applications$1,072,596
R35 · FY2017 · CA · contact PI
Cancer genes: translating basics to applications$1,062,495
R35 · FY2016 · CA · contact PI
Activation of silenced tumor suppressor genes by non-coding RNA$370,755
R01 · FY2014 · CA · contact PI
P3K, Retroviral Oncogene and Homolog of PI 3-Kinase$396,559
R01 · FY2013 · CA · contact PI
Activation of silenced tumor suppressor genes by non-coding RNA$359,288
R01 · FY2013 · CA · contact PI
The Antisense Transcriptome and the Epigenetics of Cancer.$287,431
R01 · FY2013 · CA · contact PI
P3K, Retroviral Oncogene and Homolog of PI 3-Kinase$471,870
R01 · FY2012 · CA · contact PI
Activation of silenced tumor suppressor genes by non-coding RNA$382,221
R01 · FY2012 · CA · contact PI
The Antisense Transcriptome and the Epigenetics of Cancer.$305,777
R01 · FY2012 · CA · contact PI
Inhibition of TOR and de novo protein synthesis: a pulsed SILAC database$236,875
R21 · FY2012 · AG · contact PI
P3K, Retroviral Oncogene and Homolog of PI 3-Kinase$421,871
R01 · FY2011 · CA · contact PI
Activation of silenced tumor suppressor genes by non-coding RNA$382,221
R01 · FY2011 · CA · contact PI
The Antisense Transcriptome and the Epigenetics of Cancer.$305,777
R01 · FY2011 · CA · contact PI
Inhibition of TOR and de novo protein synthesis: a pulsed SILAC database$284,250
R21 · FY2011 · AG · contact PI
P3K, Retroviral Oncogene and Homolog of PI 3-Kinase$434,918
R01 · FY2010 · CA · contact PI
Activation of silenced tumor suppressor genes by non-coding RNA$394,043
R01 · FY2010 · CA · contact PI
The Antisense Transcriptome and the Epigenetics of Cancer.$315,234
R01 · FY2010 · CA · contact PI
SMALL MOLECULES REGULATING PROTEIN-PROTEIN INTERACTIONS IN CANCER$33,501
P41 · FY2010 · RR · contact PI
P3K, Retroviral Oncogene and Homolog of PI 3-Kinase$434,918
R01 · FY2009 · CA · contact PI
SMALL MOLECULES REGULATING PROTEIN-PROTEIN INTERACTIONS IN CANCER$3,181
P41 · FY2009 · RR · contact PI
Combinatorial Chemistry and Cancer Target$1,341,169
P01 · FY2008 · CA · contact PI
TARGET-GUIDED DEVELOPMENT OF SPECIFIC AKT INHIBITORS$423,289
R01 · FY2008 · CA · contact PI
Combinatorial Chemical Libraries and Cancer Targets$347,302
P01 · FY2008 · CA · contact PI
Controlling the Max Network$242,569
R01 · FY2008 · CA · contact PI
Combinatorial Chemistry and Cancer Target$1,316,611
P01 · FY2007 · CA · contact PI
TARGET-GUIDED DEVELOPMENT OF SPECIFIC AKT INHIBITORS$435,148
R01 · FY2007 · CA · contact PI
P3K, Retroviral Oncogene and Homolog of PI 3-Kinase$418,239
R01 · FY2007 · CA · contact PI
Combinatorial Chemical Libraries and Cancer Targets$341,623
P01 · FY2007 · CA · contact PI
Controlling the Max Network$240,265
R01 · FY2007 · CA · contact PI
Combinatorial Chemistry and Cancer Target$1,331,121
P01 · FY2006 · CA · contact PI
P3K, Retroviral Oncogene and Homolog of PI 3-Kinase$430,730
R01 · FY2006 · CA · contact PI
Controlling the Max Network$247,441
R01 · FY2006 · CA · contact PI
Combinatorial Chemical Libraries and Cancer Targets$178,720
P01 · FY2006 · CA · contact PI
Combinatorial Chemistry and Cancer Target$1,330,981
P01 · FY2005 · CA
P3K, Retroviral Oncogene and Homolog of PI 3-Kinase$441,095
R01 · FY2005 · CA
Controlling the Max Network$253,395
R01 · FY2005 · CA
Combinatorial Chemical Libraries and Cancer Targets$174,389
P01 · FY2005 · CA
Combinatorial Chemistry and Cancer Target$1,263,757
P01 · FY2004 · CA
P3K, Retroviral Oncogene and Homolog of PI 3-Kinase$441,095
R01 · FY2004 · CA
Controlling the Max Network$253,395
R01 · FY2004 · CA
Combinatorial Chemical Libraries and Cancer Targets$170,983
P01 · FY2004 · CA
Administrative Core$37,953
P01 · FY2004 · CA
P3K, Retroviral Oncogene and Homolog of PI 3-Kinase$441,095
R01 · FY2003 · CA
THE ONCOGENICITY OF WINGED HELIX PROTEINS$299,551
R01 · FY2003 · CA
Potent inhibitors of Anthrax Lethal Factor$277,800
R21 · FY2003 · AI
COMBINATORIAL CHEMISTRY AND CANCER TARGETS$1,280,561
P01 · FY2002 · CA
P3K, RETROVIRAL ONCOGENE AND HOMOLOG OF PI 3-KINASE$445,829
R01 · FY2002 · CA
THE ONCOGENICITY OF WINGED HELIX PROTEINS$292,983
R01 · FY2002 · CA
Potent inhibitors of Anthrax Lethal Factor$277,800
R21 · FY2002 · AI
CORE--INSTRUMENT CORE$197,079
P01 · FY2002 · CA
CORE--ANIMAL CORE$197,079
P01 · FY2002 · CA
COMBINATORIAL LIBRARIES AND CANCER TARGETS$197,079
P01 · FY2002 · CA
Conference on Genomics/Genetics of Senescence and Cancer$5,000
R13 · FY2002 · CA
COMBINATORIAL CHEMISTRY AND CANCER TARGETS$1,180,765
P01 · FY2001 · CA
P3K, RETROVIRAL ONCOGENE AND HOMOLOG OF PI 3-KINASE$411,503
R01 · FY2001 · CA
THE ONCOGENICITY OF WINGED HELIX PROTEINS$273,330
R01 · FY2001 · CA
CORE--INSTRUMENT CORE$0
P01 · FY2001 · CA
CORE--ANIMAL CORE$0
P01 · FY2001 · CA
COMBINATORIAL LIBRARIES AND CANCER TARGETS$0
P01 · FY2001 · CA
COMBINATORIAL CHEMISTRY AND CANCER TARGETS$1,135,998
P01 · FY2000 · CA
P3K, RETROVIRAL ONCOGENE AND HOMOLOG OF PI 3-KINASE$401,884
R01 · FY2000 · CA
THE ONCOGENICITY OF WINGED HELIX PROTEINS$267,432
R01 · FY2000 · CA
CORE--INSTRUMENT CORE$149,053
P01 · FY2000 · CA
CORE--ANIMAL CORE$149,053
P01 · FY2000 · CA
COMBINATORIAL LIBRARIES AND CANCER TARGETS$149,053
P01 · FY2000 · CA